Document is current
Any future updates will be listed below
-
Authors
Griewing, Sebastian https://orcid.org/0000-0001-5355-8903
Gerber, Florian
Oftring, Zoe S. https://orcid.org/0000-0001-5473-2141
Bamberger, Jonathan https://orcid.org/0009-0002-2160-6418
Groß, Alexandra
Kalder, Matthias
Jansen, Malin
Keil, Corinna https://orcid.org/0000-0002-1455-1319
Knitza, Johannes https://orcid.org/0009-0005-9192-4026
Gremke, Niklas https://orcid.org/0000-0002-9015-3646
Wagner, Uwe
Leyer, Michael
Kuhn, Sebastian https://orcid.org/0000-0002-8031-2973
-
Funding
Funding for this research was provided by:
Philipps-Universität Marburg
- License Information
-
More Information
Article History
Received: 12 April 2026
Accepted: 22 June 2026
First Online: 29 June 2026
Declarations
:
: The study was approved by the Ethics Committee of the Department of Medicine or Philipps-University Marburg on July 8, 2025 (25–79 BO). All participants provided written consent after receiving both oral and written information about the study from the investigators. The study was conducted in accordance with the principles of the Declaration of Helsinki.
: Not Applicable.
: Sebastian Griewing received a travel grant from AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, and honoraria for lectures from Novartis Pharma GmbH, Nuremberg, Germany, and FERRING Arzneimittel GmbH, Kiel, Germany. The remaining authors have no relevant financial or non-financial interests to disclose. Butterfly Network, Inc., Burlington, Massachusetts, USA, provided two Butterfly iQ3 devices free of charge for the conduct of the study but had no role in the design, conduct, analysis, or interpretation of the study. This provision of study devices was disclosed as part of the ethics application and considered during the ethics review.
